MedPage Today July 5, 2024
— PCPs are “perfectly situated” to identify initial thinking changes of patients, expert says
Negotiations are underway in medical literature and clinics as to who should diagnose dementia, in light of new anti-amyloid monoclonal antibodies — lecanemab (Leqembi) and donanemab (Kisunla) — for early Alzheimer’s disease, new developments in biomarkers, and an anticipated increase in the number of cognitively impaired elderly adults.
The new Alzheimer’s drugs have likely increased pressure on primary care to evaluate cognitive changes so eligible people can be diagnosed sooner, noted geriatrician Nathaniel Chin, MD, of the University of Wisconsin in Madison.
“The treatments may have expanded the role of primary care to now discuss the new therapies to some degree, and to help explain who...
Today's Sponsors
Today's Sponsor